CLINICAL ROLE -
Adding Pembrolizumab to Chemotherapy Increases Pathological Complete Response, Improves Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2– Breast Cancer
pCR rates improve regardless of whether patients received full chemotherapy doses.
FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies
Trastuzumab deruxtecan and elacestrant represent important new treatment options.
Neoadjuvant Chemotherapy Could Help Patients With Breast Cancer Skip Regional Nodal Irradiation
No established standard of care currently exists after spread to the lymph nodes.
Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The combination resulted in numerically longer OS compared with an NSAI alone.
Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL
The MRD-guided treatment approach has a significant advantage over chemotherapy.
AI Model Differentiates Prefibrotic Primary Myelofibrosis From Essential Thrombocythemia With High Accuracy
It can also help identify patients who would benefit from disease-specific therapies.
Subcutaneous Daratumumab Plus VRd Significantly Improves PFS, Increases Depth of Response in Patients With Newly Diagnosed Multiple Myeloma
Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.
Assessing Clinical Trial Efficacy vs Real-World Effectiveness in the Management of Multiple Myeloma
There is a significant efficacy-effectiveness gap in standard-of-care regimens.
Gender Gap in NIH-Awarded Research Grants Persists in the Field of Nonmalignant Hematology
Further policy changes to promote gender equity may be needed.
Assessing Philadelphia-Like B-Cell ALL in a Largely Hispanic Population
Ph-like ALL may be predominantly prevalent in Hispanic and Latino populations.
From Capecitabine to Tucatinib: Data Reveal New Treatment Options for Patients
Significant study results could inform clinical practice strategies.
From Axatilimab to Zanubrutinib: Treatment Updates Abound
Presentations detail clinical trial results and focus on drugs in the pipeline.
Presentations at the ASH and SABCS Conferences Highlight Advancements in the Field of Oncology Pharmacy
2023 was an impactful year for the field of oncology pharmacy.
